Unicycive(US:UNCY) Prnewswire·2025-10-03 15:30Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, encouraging affected investors to discuss their legal options [1][3]. Group 1: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its OLC NDA [3]. - Specific claims include overstated readiness to meet FDA compliance and misrepresentation of the NDA's regulatory prospects, leading to materially false public statements [3]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, which disclosed deficiencies in cGMP compliance at a third-party vendor, Unicycive's stock price fell by $3.68, or 40.89%, closing at $5.32 per share [4]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same cGMP deficiencies, the stock price dropped by $2.03, or 29.85%, closing at $4.77 per share [5]. Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Unicycive is October 14, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member, with no impact on their ability to share in any recovery [6].